173 related articles for article (PubMed ID: 34627624)
1. Strategies for vaccine-product innovation: Creating an enabling environment for product development to uptake in low- and middle-income countries.
Giersing B; Shah N; Kristensen D; Amorij JP; Kahn AL; Gandrup-Marino K; Jarrahian C; Zehrung D; Menozzi-Arnaud M
Vaccine; 2021 Dec; 39(49):7208-7219. PubMed ID: 34627624
[TBL] [Abstract][Full Text] [Related]
2. Vaccine innovation prioritisation strategy: Findings from three country-stakeholder consultations on vaccine product innovations.
Mvundura M; Frivold C; Janik Osborne A; Soni P; Robertson J; Kumar S; Anena J; Gueye A; Menozzi-Arnaud M; Giersing B; Kahn AL; Scarna T; Kristensen D
Vaccine; 2021 Dec; 39(49):7195-7207. PubMed ID: 34412922
[TBL] [Abstract][Full Text] [Related]
3. Two decades of vaccine innovations for global public good: Report of the Developing Countries' Vaccine Manufacturers Network 20th meeting, 21-23 october 2019, Rio de Janeiro, Brazil.
Pagliusi S; Dennehy M; Homma A
Vaccine; 2020 Aug; 38(36):5851-5860. PubMed ID: 32535016
[TBL] [Abstract][Full Text] [Related]
4. Opportunities to accelerate immunization progress in middle-income countries.
Zhu J; Cole CB; Fihman J; Adjagba A; Dasic M; Cernuschi T
Vaccine; 2023 Jul; ():. PubMed ID: 37460357
[TBL] [Abstract][Full Text] [Related]
5. Costs of vaccine programs across 94 low- and middle-income countries.
Portnoy A; Ozawa S; Grewal S; Norman BA; Rajgopal J; Gorham KM; Haidari LA; Brown ST; Lee BY
Vaccine; 2015 May; 33 Suppl 1():A99-108. PubMed ID: 25919184
[TBL] [Abstract][Full Text] [Related]
6. Effect of donor funding for immunization from Gavi and other development assistance channels on vaccine coverage: Evidence from 120 low and middle income recipient countries.
Ikilezi G; Augusto OJ; Dieleman JL; Sherr K; Lim SS
Vaccine; 2020 Jan; 38(3):588-596. PubMed ID: 31679863
[TBL] [Abstract][Full Text] [Related]
7. Trends in vaccine investment in middle income countries.
Onishchenko K; Hill S; Wasserman M; Jones C; Moffatt M; Ruff L; Pugh SJ
Hum Vaccin Immunother; 2019; 15(10):2378-2385. PubMed ID: 30843757
[TBL] [Abstract][Full Text] [Related]
8. Potential use of microarray patches for vaccine delivery in low- and middle- income countries.
Peyraud N; Zehrung D; Jarrahian C; Frivold C; Orubu T; Giersing B
Vaccine; 2019 Jul; 37(32):4427-4434. PubMed ID: 31262587
[TBL] [Abstract][Full Text] [Related]
9. Vaccines, inspiring innovation in health.
Pagliusi S; Dennehy M; Kim H;
Vaccine; 2018 Nov; 36(48):7430-7437. PubMed ID: 29789241
[TBL] [Abstract][Full Text] [Related]
10. A global collaboration to advance vaccine product innovations - The Vaccine Innovation Prioritisation Strategy.
Kristensen D; Giersing B; Hickling J; Kazi F; Scarna T; Kahn AL; Hsu V; Gandrup-Marino K; Menozzi-Arnaud M
Vaccine; 2021 Dec; 39(49):7191-7194. PubMed ID: 34175125
[No Abstract] [Full Text] [Related]
11. Costs of Immunization Programs for 10 Vaccines in 94 Low- and Middle-Income Countries From 2011 to 2030.
Sim SY; Watts E; Constenla D; Huang S; Brenzel L; Patenaude BN
Value Health; 2021 Jan; 24(1):70-77. PubMed ID: 33431156
[TBL] [Abstract][Full Text] [Related]
12. Controlled temperature chain for vaccination in low- and middle-income countries: a realist evidence synthesis.
Seaman CP; Kahn AL; Kristensen D; Steinglass R; Spasenoska D; Scott N; Morgan C
Bull World Health Organ; 2022 Aug; 100(8):491-502. PubMed ID: 35923285
[TBL] [Abstract][Full Text] [Related]
13. Costs of introducing and delivering HPV vaccines in low and lower middle income countries: inputs for GAVI policy on introduction grant support to countries.
Levin A; Wang SA; Levin C; Tsu V; Hutubessy R
PLoS One; 2014; 9(6):e101114. PubMed ID: 24968002
[TBL] [Abstract][Full Text] [Related]
14. Challenges of vaccine presentation and delivery: How can we design vaccines to have optimal programmatic impact?
Giersing BK; Kahn AL; Jarrahian C; Mvundura M; Rodriguez C; Okayasu H; Zehrung D
Vaccine; 2017 Dec; 35(49 Pt A):6793-6797. PubMed ID: 28566254
[TBL] [Abstract][Full Text] [Related]
15. Pro-equity immunization and health systems strengthening strategies in select Gavi-supported countries.
Dadari I; Higgins-Steele A; Sharkey A; Charlet D; Shahabuddin A; Nandy R; Jackson D
Vaccine; 2021 Apr; 39(17):2434-2444. PubMed ID: 33781603
[TBL] [Abstract][Full Text] [Related]
16. Improving Middle-Income Countries Access to Vaccines. A Blueprint to Overcome Current Challenges.
Espinal C; Becerra-Posada F; Torres JR
Ann Glob Health; 2023; 89(1):80. PubMed ID: 38025920
[TBL] [Abstract][Full Text] [Related]
17. Challenges to sustainable immunization systems in Gavi transitioning countries.
Cernuschi T; Gaglione S; Bozzani F
Vaccine; 2018 Oct; 36(45):6858-6866. PubMed ID: 30268735
[TBL] [Abstract][Full Text] [Related]
18. Data and product needs for influenza immunization programs in low- and middle-income countries: Rationale and main conclusions of the WHO preferred product characteristics for next-generation influenza vaccines.
Neuzil KM; Bresee JS; de la Hoz F; Johansen K; Karron RA; Krishnan A; Madhi SA; Mangtani P; Spiro DJ; Ortiz JR;
Vaccine; 2017 Oct; 35(43):5734-5737. PubMed ID: 28893473
[TBL] [Abstract][Full Text] [Related]
19. Economic Benefits of Immunization for 10 Pathogens in 94 Low- and Middle-Income Countries From 2011 to 2030 Using Cost-of-Illness and Value-of-Statistical-Life Approaches.
Watts E; Sim SY; Constenla D; Sriudomporn S; Brenzel L; Patenaude B
Value Health; 2021 Jan; 24(1):78-85. PubMed ID: 33431157
[TBL] [Abstract][Full Text] [Related]
20. Accelerating the development of vaccine microarray patches for epidemic response and equitable immunization coverage requires investment in microarray patch manufacturing facilities.
Scarnà T; Menozzi-Arnaud M; Friede M; DeMarco K; Plopper G; Hamer M; Chakrabarti A; Gilbert PA; Jarrahian C; Mistilis J; Hesselink R; Gandrup-Marino K; Amorij JP; Giersing B
Expert Opin Drug Deliv; 2023 Mar; 20(3):315-322. PubMed ID: 36649573
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
